Peptide

Sermorelin

GHRH(1-29) amide

Evidence TierBWADA PROHIBITED

tuneTypical Dose

~30 mcg/kg/day SC in selected historical pediatric treatment studies

watchEffect Window

3-12 months for growth outcomes

lockCompliance

WADA PROHIBITED

Overview

Clinical Summary

Sermorelin is a GHRH analog that stimulates endogenous growth hormone release. It is used for growth hormone axis testing and for IGF-1 elevation claims, with limited outcomes evidence in healthy users.

Sermorelin increases growth hormone secretion and has endocrine use history in selected clinical contexts. Claims include improved sleep quality and body composition, but controlled outcomes evidence in healthy users is limited. Minority interest includes improved recovery in older adults with low IGF-1, though data are sparse. Benefits are better supported for hormonal stimulation than for validated functional improvements.

Pituitary GHRH receptor agonism leading to GH pulses and downstream IGF-1 signaling.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Growth-velocity and GH-axis stimulation in GH-deficient children
  • Improved GH provocation response in selected diagnostic protocols

Secondary Outcomes

  • No high-quality healthy-performance outcomes established

Safety

Contraindications and Interactions

Contraindications

  • Active malignancy
  • Pregnancy/lactation
  • Uncontrolled endocrine disease

Side effects

  • Transient facial flushing
  • Injection-site pain

Interactions

  • Uncharacterized with other GH secretagogues

Avoid if

  • Healthy users seeking general wellness goals
  • Undiagnosed growth complaints

Evidence

Study-level References

sermorelin-SRC-001Review of clinical and diagnostic studies
Sourceopen_in_new

https://pubmed.ncbi.nlm.nih.gov/18031173/ doi:10.2165/00063030-199912020-00007

Population: Children with idiopathic GH deficiency and pediatric diagnostic cohorts

Dose protocol: 1 mcg/kg IV test, ~30 mcg/kg/day SC treatment in selected analyses

Key findings: Evidence supports GH response and growth-velocity benefit in pediatric deficiency, with lower response than somatropin in direct references.

Notes: Data quality is historical with varying comparators and incomplete modern trial standards.

Paper content

Evidence supports GH response and growth-velocity benefit in pediatric deficiency, with lower response than somatropin in direct references.

sermorelin-SRC-002Randomized clinical trial with growth hormone comparator
Sourceopen_in_new

https://pubmed.ncbi.nlm.nih.gov/9039344/

Population: Adults with GH deficiency

Dose protocol: Growth hormone replacement comparator trial (not sermorelin-treated arm as monotherapy) for endocrine physiology context.

Key findings: Demonstrates endocrine endpoint sensitivity to GH axis changes but does not establish sermorelin superiority.

Notes: Useful background on endocrine outcomes, not primary proof for sermorelin effectiveness.

Paper content

Demonstrates endocrine endpoint sensitivity to GH axis changes but does not establish sermorelin superiority.

sermorelin-SRC-003Historical uncontrolled/limited cohorts
Sourceopen_in_new

https://pubmed.ncbi.nlm.nih.gov/18046908/ (review/editorial context on sermorelin in endocrine insufficiency; PMID: 18046908)

Population: Growth hormone deficiency populations

Dose protocol: Various reported clinic protocols

Key findings: Conflicting and low-quality data in small cohorts.

Notes: Excluded as primary evidence due low traceability.

Paper content

Conflicting and low-quality data in small cohorts.

sermorelin-SRC-004Narrative review.
Sourceopen_in_new

Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. doi:10.21037/tau.2019.11.30. PMID:32257855.

Population: Hypogonadal males considered for adjunctive GH secretagogue therapy.

Dose protocol: Narrative review of GH secretagogues (sermorelin, GHRP-2, GHRP-6, ibutamoren, ipamorelin) as adjuncts in hypogonadal males

Key findings: GH secretagogues including sermorelin can stimulate GH and IGF-1 and may improve body composition by reducing fat accumulation and supporting lean mass. Clinical evidence remains limited.

Notes: Review-level evidence only. Confirms that body composition claims for sermorelin rest on physiological reasoning rather than robust trial data.

Paper content

This narrative review examined growth hormone secretagogues, including sermorelin, as potential adjunctive therapy for body composition management in hypogonadal males. The authors found that these agents can stimulate GH and IGF-1 and may improve body composition by reducing fat accumulation and muscle loss. However, they acknowledged that limited clinical evidence constrains understanding of their therapeutic applications. The review positions GH secretagogues as promising but insufficiently validated adjuncts to testosterone therapy, reinforcing that the body composition claims for sermorelin rest on physiological reasoning rather than robust trial data.

Guides

Setup

Help